Allergan has been acquiring small companies after Pfizer walked away from the $160 billion merge and now has its eyes set on Regeneron and Biogen.
Allergan Plc. faced a massive blow when Pfizer Incorporation walked away from the year planned merge between the two worth $160 billion. This was because of the changes in rules and regulations of the US Treasury to stop corporate inversions form happening and companies being able to avoid US taxes. The Botox maker does not seem to be so hurt and since then has been acquiring smaller companies such as Topokine Therapeutics for $45 million cash up front getting into the biotech business and manufacturing even more cosmetic drugs. Now it has its eyes on Biogen and Regeneron.
Allergan is seeking for companies that have potential to grow and a strong drug portfolio with the major focus on research and development. This was the Botox makers’ plans even before the merge its planned merge with Pfizer and it seems to stick to it even after the failure of the takeover. It is doing so that success and more profit can be achieved in the long run and even expansions of its products portfolio.
The pharmaceutical company has enough money to takeover smaller companies with strong success potential and is doing that only, which will help make its R&D department become stronger, creative and innovative. It is focusing on many biotech companies as it seeks to grow in the sector in the future. Regeneron and Biogen both qualify for the things the Botox maker is looking for, consisting of synergistic pipelines that might help the company speed its growth up.
This is not the only thing Allergan has been looking at, it also looking at Bausch & Lomb, an eye care division which was sold to Valeant for $8.7 billion back in 2013 by Brent Saunders, who is now the CEO of the Ireland based Pharma giant. Brent might want this strong asset back in his power as he was the CEO of Valeant when it bought B&L.
However that might become difficult to achieve since the recent addition to the board of Valeant, Bill Ackman said that the company is only planning to sell non-core assets and this is not one of them. Biogen seems attractive to Allergan because of its strong portfolio in central nervous system diseases and currently the Ireland Company’s CNS drugs do not overlap with Biogen drugs.
The merge with Biogen will help Allergan expand itself in the market of neurology in the future and set a strong foothold. There are some setbacks such as Biogen Alzheimer’s franchise but nothing can be achieved without risks.
When it comes to Regeneron, acquiring it will help the company get into the dermatology market even more; it even shows strong growth potential, the yearly rate being 17% this year till 2019, which is double of Allergan. No expectation can be made as to when the Botox maker might make a deal but it will not happen anytime soon, it will only happen once it switches its genetics unit to Teva which has been postponed to Jun, while the FTC reviews the portfolio.
Allergan Plc. faced a massive blow when Pfizer Incorporation walked away from the year planned merge between the two worth $160 billion. This was because of the changes in rules and regulations of the US Treasury to stop corporate inversions form happening and companies being able to avoid US taxes. The Botox maker does not seem to be so hurt and since then has been acquiring smaller companies such as Topokine Therapeutics for $45 million cash up front getting into the biotech business and manufacturing even more cosmetic drugs. Now it has its eyes on Biogen and Regeneron.
Allergan is seeking for companies that have potential to grow and a strong drug portfolio with the major focus on research and development. This was the Botox makers’ plans even before the merge its planned merge with Pfizer and it seems to stick to it even after the failure of the takeover. It is doing so that success and more profit can be achieved in the long run and even expansions of its products portfolio.
The pharmaceutical company has enough money to takeover smaller companies with strong success potential and is doing that only, which will help make its R&D department become stronger, creative and innovative. It is focusing on many biotech companies as it seeks to grow in the sector in the future. Regeneron and Biogen both qualify for the things the Botox maker is looking for, consisting of synergistic pipelines that might help the company speed its growth up.
This is not the only thing Allergan has been looking at, it also looking at Bausch & Lomb, an eye care division which was sold to Valeant for $8.7 billion back in 2013 by Brent Saunders, who is now the CEO of the Ireland based Pharma giant. Brent might want this strong asset back in his power as he was the CEO of Valeant when it bought B&L.
However that might become difficult to achieve since the recent addition to the board of Valeant, Bill Ackman said that the company is only planning to sell non-core assets and this is not one of them. Biogen seems attractive to Allergan because of its strong portfolio in central nervous system diseases and currently the Ireland Company’s CNS drugs do not overlap with Biogen drugs.
The merge with Biogen will help Allergan expand itself in the market of neurology in the future and set a strong foothold. There are some setbacks such as Biogen Alzheimer’s franchise but nothing can be achieved without risks.
When it comes to Regeneron, acquiring it will help the company get into the dermatology market even more; it even shows strong growth potential, the yearly rate being 17% this year till 2019, which is double of Allergan. No expectation can be made as to when the Botox maker might make a deal but it will not happen anytime soon, it will only happen once it switches its genetics unit to Teva which has been postponed to Jun, while the FTC reviews the portfolio.